Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medicine and Aging Science, Institute of "Clinica Medica", "G. D'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Medicina (Kaunas). 2024 Oct 31;60(11):1781. doi: 10.3390/medicina60111781.
Peripheral artery disease (PAD) is still the least studied and evaluated form in clinical practice among atherosclerotic pathologies, despite the increased mortality and comorbidities related to it. The relationship between steatotic liver disease and an increased risk of cardiovascular disease has been extensively documented. The purpose of this work is to perform a review of the evidence linking NAFLD or MASLD to PAD, and examine possible clinical scenarios that arise from this new terminology. The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) includes the presence of cardiometabolic risk factors and hepatic steatosis without any other underlying causes of hepatic steatosis; this terminology, coined in the hepatological field, could generate confusion, especially in the initial stages of its diffusion and among different medical specialists. Some recent data in the literature have strengthened the evidence of a pathological link between hepatic metabolic alteration (NAFLD or MAFLD) and PAD.
外周动脉疾病（PAD）仍然是动脉粥样硬化性疾病中在临床实践中研究和评估最少的一种疾病，尽管它与死亡率增加和相关合并症有关。脂肪性肝病与心血管疾病风险增加之间的关系已得到广泛证实。本研究旨在回顾将非酒精性脂肪性肝病（NAFLD）或代谢相关脂肪性肝病（MAFLD）与 PAD 联系起来的证据，并探讨由此产生的可能的临床情况。代谢相关脂肪性肝病（MASLD）的新定义包括存在代谢性心血管危险因素和肝脂肪变性，而无任何其他导致肝脂肪变性的原因；这一术语是在肝脏疾病领域提出的，可能会造成混淆，尤其是在其传播的初始阶段和不同医学专家之间。文献中的一些最新数据强化了肝代谢改变（NAFLD 或 MAFLD）与 PAD 之间存在病理性联系的证据。
